Pages that link to "Q35621653"
Jump to navigation
Jump to search
The following pages link to Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma (Q35621653):
Displaying 50 items.
- Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy (Q26796309) (← links)
- Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 (Q26796316) (← links)
- Pathways and therapeutic targets in melanoma (Q26865736) (← links)
- Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape (Q27691824) (← links)
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study (Q27852083) (← links)
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. (Q27853331) (← links)
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials (Q31143336) (← links)
- Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date (Q33887664) (← links)
- Understanding the biology of melanoma and therapeutic implications (Q33978378) (← links)
- Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia (Q34052520) (← links)
- Therapy for metastatic melanoma: the past, present, and future. (Q34183225) (← links)
- Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma (Q34662717) (← links)
- Genotyping of cutaneous melanoma (Q34667738) (← links)
- Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies (Q35154039) (← links)
- Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach (Q35273776) (← links)
- Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? (Q35794989) (← links)
- The immune-related role of BRAF in melanoma (Q35847321) (← links)
- NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas (Q35885523) (← links)
- Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation (Q36260662) (← links)
- Drug targets and predictive biomarkers in the management of metastatic melanoma (Q36441552) (← links)
- Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab (Q36938806) (← links)
- High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines (Q37592392) (← links)
- Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. (Q37650720) (← links)
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management (Q37689575) (← links)
- BRAF and beyond: Tailoring strategies for the individual melanoma patient (Q37702515) (← links)
- Integrating new therapies in the treatment of advanced melanoma (Q38022444) (← links)
- Which drug, and when, for patients with BRAF-mutant melanoma? (Q38078136) (← links)
- Update on the targeted therapy of melanoma. (Q38082713) (← links)
- Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma (Q38124821) (← links)
- Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies (Q38147850) (← links)
- The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. (Q38148745) (← links)
- Intra-lesional interleukin-2 therapy for in transit melanoma. (Q38181030) (← links)
- Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. (Q38195656) (← links)
- Recent developments in the medical and surgical treatment of melanoma (Q38200004) (← links)
- Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma (Q38312053) (← links)
- Treatment for metastatic melanoma: a new and evolving era. (Q38366422) (← links)
- Treatment of NRAS-mutant melanoma. (Q38386344) (← links)
- NRAS-mutant melanoma: current challenges and future prospect (Q38598958) (← links)
- Biomarkers in Melanoma: Lessons from Translational Medicine (Q38652178) (← links)
- A review of binimetinib for the treatment of mutant cutaneous melanoma (Q38674107) (← links)
- Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma (Q38689912) (← links)
- The impact of sequencing on diagnosis and treatment of malignant melanoma (Q38715265) (← links)
- Harnessing the immune system for the treatment of melanoma: current status and future prospects. (Q38806243) (← links)
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma (Q39078976) (← links)
- The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. (Q39253839) (← links)
- Interaction of molecular alterations with immune response in melanoma. (Q39329609) (← links)
- Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2. (Q41667279) (← links)
- High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. (Q41706967) (← links)
- Melanoma driver mutations and immune therapy (Q42034581) (← links)
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. (Q43147493) (← links)